Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy

NCT02671864 · Unknown status

Last updated 2026-05-28

This clinical trial is studying whether incretin-mimetic hypoglycemic drugs are linked to severe retinopathy in people with type 2 diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) study

Participants 7,200 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2016-04 · est. completion 2025-04

Where 2 sites · France

What this study is testing ClinicalTrials.gov NCT02671864 ↗

Description as written by the study sponsor.

Experimental data suggest that GLP-1 promote endothelial cell growth and angiogenesis which may have beneficial effects on the cardiovascular system but harmful effects on the retina . This project investigate the possible link between incretin therapy and Severe Diabetic Retinopathy. The prevalence of severe DR in patients exposed to incretin therapy (GLP-1 analogs or DPP4 inhibitors) is compared to that in non-exposed patients to these antidiabetic classes.

Treatments tested

1: incretin-based therapy Other
2: other antidiabetic Other

Main thing measured	Prevalence of Severe DR at V1 (inclusion)
Sponsor	Assistance Publique - Hôpitaux de Paris
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02671864 ↗